Kay Tetzlaff, MD is a board-certified pulmonologist and internist with 20+ years of biopharma leadership spanning early development through global registration in respiratory and inflammatory diseases. He has recently served in Lead Clinical Development advisory roles at multiple biotech companies, including Agomab SV, WindwardBio AG, Plythera, and Orphai Therapeutics.
Previously, Dr. Tetzlaff served as Vice President, Medicine—Inflammation/Respiratory at Boehringer Ingelheim, where he built and led a >70-person medical organization, oversaw a ~€230M clinical budget, advanced a broad immunology portfolio, and helped accelerate the spesolimab NDA in generalized pustular psoriasis to launch. He also led medical teams through successful OFEV® CHMP/FDA oral meetings in SSc-ILD and PF-ILD. Earlier at BI, he co-led the global clinical programs for tiotropium/olodaterol (SPIOLTO® Respimat®) and olodaterol (STRIVERDI® Respimat®), steered the WISDOM COPD study, and contributed to endpoint innovation with the CASA-Q PRO instrument.
Dr. Tetzlaff is Associate Professor (Univ. of Tübingen), previously held consultant posts at University Hospital Kiel and the German Naval Medical Institute, and has authored 120+ peer-reviewed publications. Honors include Boehringer Ingelheim’s President’s Award for contributions to the Spiriva® FDA PADAC. Comment end
